Is Compounded Semaglutide & Tirzepatide Legal in Your State? (2026 Tracker)

Searching whether compounded semaglutide or tirzepatide is legal in your state turns up a lot of state-by-state pages that all say the same thing — because the rules are almost entirely federal. The FDA, not your state, decided that mass compounding of these drugs had to end when the shortages resolved in 2025. So instead of repeating one national rule fifty times, this page gives you the part that actually matters: the national timeline of what changed and when, the narrow personalized-compounding door that still exists everywhere, the few states that have added their own enforcement or guidance, and how telehealth shipping works across state lines. Every state entry is sourced to a primary document. For what to do about it — brand, the oral pill, or tapering off — see our compounded-GLP-1 options guide.

The short answer

• It is a federal question first. Compounded semaglutide and tirzepatide were only legal at scale because the drugs were on the FDA shortage list. Once the FDA declared the shortages over (tirzepatide Dec 2024, semaglutide Feb 2025), the legal basis for compounding copies ended nationwide — in every state at once.
• A narrow personalized door remains everywhere. A state-licensed (503A) pharmacy can still compound a genuinely non-copy formulation when your prescriber documents a clinically significant reason specific to you. This is the same federal standard in all 50 states — cost and convenience do not qualify.
• Only a handful of states add their own layer. Most states simply follow the federal rule. A few — Mississippi, Ohio, Kentucky, Oregon, California, and a couple with active attorney-general enforcement (Connecticut, Alabama) — have issued their own guidance or brought cases. Those are the ones worth knowing.
• The big 2026 change is still a proposal. In May 2026 the FDA proposed permanently barring 503B outsourcing facilities from compounding these drugs. It is pending review, not a finalized ban — and it, too, would apply nationally.

The national timeline: how compounding wound down

These dates are federal and apply in every state. Note that the deadlines were drug-specific — tirzepatide's came first^[1], semaglutide's a couple of months later^[2] — so a page that lists one set of dates for all GLP-1s is wrong for tirzepatide.

What is still legal anywhere in the US

In all 50 states, a state-licensed (503A) pharmacy may still compound semaglutide or tirzepatide only when it is not "essentially a copy" of the FDA-approved product — meaning your prescriber documents a clinically significant change for you specifically (for example, a documented allergy to an inactive ingredient, or a medically necessary strength the manufacturer does not make)^[3]. A blanket "weight loss plus B12" formulation does not qualify. The FDA has also said it will generally not pursue a 503A pharmacy that fills four or fewer of a given compounded product per month. This is federal policy — it is the same standard in Texas, California, and everywhere else.

States that have taken their own action

Beyond the federal rule, a small number of states have layered on their own guidance or enforcement. These are the ones with a genuinely state-specific fact — each is linked to its primary source. Every other state simply follows the federal framework above.

• Mississippi — the strictest. The state Board of Medical Licensure (not the pharmacy board) permits only drugs with an FDA weight-loss indication to be prescribed for weight loss, effectively barring off-label and compounded semaglutide, and advises practitioners to stop prescribing it. The Board of Pharmacy issued separate compounding guidance, AG Lynn Fitch put out a May 2025 consumer warning, and 2026 House Bill 1136 would write an "obesity medicine" framework into state law. MS Board of Medical Licensure guidance.
• Ohio — the Board of Pharmacy's July 17, 2025 GLP-1 guidance spells out that semaglutide and tirzepatide can no longer be compounded as copies, and requires the prescriber to document a patient-specific "significant difference" on the order. Ohio Board of Pharmacy guidance (PDF)^[4].
• Kentucky — the Board of Pharmacy's 2025 guidance states that under 201 KAR 2:076, pharmacies generally may not compound semaglutide or tirzepatide as copies of the commercial drugs, allowing it only in narrow patient-specific circumstances. Kentucky Board of Pharmacy guidance (PDF)^[5].
• Oregon — the Board of Pharmacy's Statement on Semaglutide (adopted Feb 6, 2025) reiterates that compounding semaglutide and other GLP-1 agonists is prohibited except when the drug is discontinued, on the FDA shortage list, or a documented individual medical need exists. Oregon Board of Pharmacy position statements^[6].
• California — the Board of Pharmacy adopted revised "essentially a copy" compounding regulations in 2025, and over the summer inspectors began flagging compounded GLP-1s during routine pharmacy surveys, exposing pharmacies with insufficient documentation to discipline. California Board of Pharmacy regulations.
• Connecticut — on May 21, 2025 the Attorney General sent notice letters warning clinics and med spas to stop marketing compounded GLP-1s, and sued a bootleg peptide-powder distributor (Triggered Brand); the case later settled for a $300,000 judgment suspended after an $18,500 payment. Connecticut AG press release.
• Alabama — in November 2025 the Attorney General obtained a restraining order and asset freeze against a Cullman clinic (Aurora IV and Wellness) for injecting patients with "research-grade" semaglutide and tirzepatide marketed as pharmaceutical-grade; the clinic permanently closed under a January 2026 settlement. Alabama AG settlement.

Nationally, in February 2025 a coalition of 38 state attorneys general urged the FDA to act against counterfeit and illegally imported GLP-1 drugs entering the US supply chain — a sign of how much of the enforcement energy has shifted to the states even though the core rules remain federal.

Telehealth: can an out-of-state pharmacy still ship compounded GLP-1 to me?

This is the one place state lines matter mechanically, but the principle is uniform: the prescriber must be licensed in the state where you are physically located, and any pharmacy shipping to you must hold that state's nonresident (out-of-state) pharmacy license. What differs between states is only the registration paperwork — not whether compounding itself is allowed, which is the federal question above. So if a telehealth service is still offering "compounded" semaglutide or tirzepatide after the 2025 deadlines, the state-license question is secondary to the real one: does the prescription meet the federal personalized-compounding standard, or is it a copy that should no longer be made at all?

So what should I actually do?

If your compounded prescription is ending, the legal-status map above matters less than your next move. The manufacturers cut self-pay brand prices sharply in 2025-2026, there is now an oral pill, and tapering off is a legitimate (if regain-prone) choice. We walk through all four paths — with the current numbers — in the compounded-GLP-1 options guide, compare direct-pay costs in the cheapest-GLP-1 buyer's guide, and rank the legitimate telehealth providers on our semaglutide and tirzepatide pages. If you are switching drugs, always restart at the lowest dose — see the switching guide.